Receptor-binding domain-based immunoassays for serosurveillance differentiate efficiently between SARS-CoV2-exposed

Jorge Pulido1, Marga García-Durán1, Ricardo Fernández-Antonio2

  • 1Departments of R&D, Eurofins-Ingenasa, Madrid, Spain.